Sichuan Yingrui Pharmaceutical Technology

Sichuan Yingrui Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in Chengdu, China, specializing in the development of next-generation small molecule drugs. The company utilizes a proprietary structure-based drug design (SBDD) platform to address unmet medical needs in oncology, with a particular emphasis on synthetic lethality and precision oncology. Its lead program, YR-001, is a highly selective USP1 inhibitor currently in Phase 1 clinical trials for patients with advanced solid tumors, specifically targeting those with DNA damage repair deficiencies. Beyond USP1, the company is advancing a robust pipeline of candidates targeting KRAS G12C and SOS1. Sichuan Yingrui aims to provide innovative and affordable therapeutic solutions through efficient internal R&D and strategic collaborations within the Tianfu International Bio-Town ecosystem.